Geode Capital Management, LLC Immuneering Corp Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Immuneering Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 462,520 shares of IMRX stock, worth $661,403. This represents 0.0% of its overall portfolio holdings.

Number of Shares

462,520

Previous 444,233 4.12%

Holding current value

$661,403

Previous $3.27 Million 59.08%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.91 - $7.32 $34,928 - $133,860	18,287 Added 4.12%	462,520 $1.34 Million
Q4 2023 Feb 13, 2024	BUY	$4.84 - $8.44 $55,800 - $97,304	11,529 Added 2.66%	444,233 $3.27 Million
Q3 2023 Nov 13, 2023	BUY	$7.21 - $10.68 $319,965 - $473,957	44,378 Added 11.43%	432,704 $3.32 Million
Q2 2023 Aug 11, 2023	BUY	$6.49 - $13.36 $1.42 Million - $2.93 Million	219,107 Added 129.48%	388,326 $3.94 Million
Q4 2022 Feb 13, 2023	SELL	$4.09 - $10.24 $1,521 - $3,809	-372 Reduced 0.22%	169,219 $820,000

Q3 2022 Nov 14, 2022	BUY	$5.0 - $12.85 $474,955 - $1.22 Million	94,991 Added 127.33%	169,591 $2.43 Million
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $637,244 - $1.28 Million	-163,816 Reduced 68.71%	74,600 $403,000
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $676,768 - $1.78 Million	104,601 Added 78.17%	238,416 $1.54 Million
Q4 2021 Feb 11, 2022	BUY	$16.12 - $31.02 $185,315 - $356,605	11,496 Added 9.4%	133,815 $2.16 Million
Q3 2021 Nov 12, 2021	BUY	$17.0 - $32.84 $2.08 Million - $4.02 Million	122,319 New	122,319 $3.25 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $37.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Immuneering Corp Transaction History